Safety, immunogenicity, and protection provided by unadjuvanted and adjuvanted formulations of a recombinant plant-derived virus-like particle vaccine candidate for COVID-19 in nonhuman primates.
Pillet S, Arunachalam PS, Andreani G, Golden N, Fontenot J, Aye PP, Röltgen K, Lehmicke G, Gobeil P, Dubé C, Trépanier S, Charland N, D'Aoust MA, Russell-Lodrigue K, Monjure C, Blair RV, Boyd SD, Bohm RP, Rappaport J, Villinger F, Landry N, Pulendran B, Ward BJ.
Pillet S, et al.
Cell Mol Immunol. 2022 Feb;19(2):222-233. doi: 10.1038/s41423-021-00809-2. Epub 2022 Jan 5.
Cell Mol Immunol. 2022.
PMID: 34983950
Free PMC article.